Trial Profile
A Double Blind, Placebo Controlled, Parallel Study to Evaluate Effects of Repeat Doses of Rilapladib on Platelet Aggregation in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Oct 2023
Price :
$35
*
At a glance
- Drugs Rilapladib (Primary)
- Indications Atherosclerosis
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 20 Dec 2012 New trial record